Seguimiento Farmacoterapéutico en pacientes con VIH/SIDA atendidos en el Hospital Daniel A. Carrión, Huancayo 2024
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
DOI
Abstract
El objetivo de la siguiente investigación es realizar el seguimiento Farmacoterapéutico en pacientes con VIH-SIDA atendidos en el Hospital Daniel A. Carrión, Huancayo 2024. Como método se utilizó el estudio prospectivo, aplicativo, descriptivo, transversal y no experimental. Los resultados determinaron que el 25,6% de los pacientes encuestados presentaron mayormente PRM1. Referente a las RAMs que presentan los pacientes con VIH -SIDA el 25,6% de los pacientes presentaron dolor de cabeza como reacción adversa a los medicamentos y el 43,0% de las IM presentados en los pacientes fue por Zidovudina. Referente a los posibles Interacciones Medicamentosas el 52,3% de los pacientes presentaron IM de tipo Farmacodinámica.
The objective of the following research is to conduct pharmacotherapeutic monitoring in patients with HIV-AIDS treated at the Daniel A. Carrión Hospital, Huancayo 2024. A prospective, applied, descriptive, cross-sectional, and non-experimental study was used as the method. The results determined that 25.6% of the patients surveyed mainly presented PRM1. Regarding the ADRs presented by patients with HIV-AIDS, 25.6% of patients presented headaches as an adverse reaction to the medications, and 43.0% of the DMIs presented in patients were due to Zidovudine. Regarding possible drug interactions, 52.3% of patients presented pharmacodynamic DMIs.
The objective of the following research is to conduct pharmacotherapeutic monitoring in patients with HIV-AIDS treated at the Daniel A. Carrión Hospital, Huancayo 2024. A prospective, applied, descriptive, cross-sectional, and non-experimental study was used as the method. The results determined that 25.6% of the patients surveyed mainly presented PRM1. Regarding the ADRs presented by patients with HIV-AIDS, 25.6% of patients presented headaches as an adverse reaction to the medications, and 43.0% of the DMIs presented in patients were due to Zidovudine. Regarding possible drug interactions, 52.3% of patients presented pharmacodynamic DMIs.